Aurisco Pharmaceutical (605116.SH) subsidiary obtains registration approval for combined packaging of estradiol tablets and estradiol dienogest tablets.

Aurisco Pharmaceutical (605116.SH) announced that its wholly-owned subsidiary, Yangzhou Aurisco Pharmaceutical Co., Ltd. (referred to as "Yangzhou Aurisco Pharmaceutical"), has received a drug registration certificate issued by the National Medical Products Administration for a combination package of estradiol tablets and estradiol dienogest tablets. This medication is used to treat perimenopausal syndrome caused by natural or surgical menopause. The estradiol tablets/estradiol dienogest tablets combination package from Yangzhou Aurisco Pharmaceutical (marketed under the trademark "Aoshutong") obtained the drug registration approval according to the new registration classification method for chemical drugs. This will enhance the company's market competitiveness in the field of this medication, and the approval of this new product for domestic sales is expected to have a positive impact on the company's business performance.